Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.2
49.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Eckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler Strahlen und Medizintechnik AG
Cost of Revenue
Eckert & Ziegler Strahlen und Medizintechnik AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Cost of Revenue
-€216.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Cost of Revenue
-€927.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Stratec SE
XETRA:SBS
|
Cost of Revenue
-€182.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Cost of Revenue
-€13.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Cost of Revenue
-€1.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Sartorius AG
XETRA:SRT
|
Cost of Revenue
-€1.9B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-16%
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
See Also
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue?
Cost of Revenue
-216.7m
EUR
Based on the financial report for Sep 30, 2024, Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue amounts to -216.7m EUR.
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-13%
Over the last year, the Cost of Revenue growth was -67%. The average annual Cost of Revenue growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been -37% over the past three years , -19% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet
